CLOV
Clover Health Investments, Corp · Healthcare · Healthcare Plans
$4.41
-1.23% today · -3.40% 1W
Nov 2 close or latest
Meta Analyst score Buy 4.1/10 (+0.57 raw)
Every firm's latest rating in the past year, each weighted by its age (a 3-month-old call counts half as much as today's), and pulled toward the typical S&P 500 score (+0.63) as if that were 3 more fresh ratings, so a score from few or old calls says less. 3 firms, 1 with a call in the past 3 months.
| Firm | Latest rating | Date | Weight |
|---|---|---|---|
| UBS | Neutral | Aug 6, 2026 | 12% |
| Canaccord Genuity | Buy | Jul 21, 2026 | 11% |
| Leerink Partners | Market Perform | Mar 5, 2026 | 4% |
Buy is what the ratings average to, +0.57 on a scale from −2 (strong sell) to +2 (strong buy). 4.1/10 means better than 41% of S&P 500 stocks (503 scored, Nov 1, 2026): analysts rarely say sell, so most stocks land between +0.4 and +0.8, and the 0–10 shows where this one sits among them.
No analyst coverage on record for CLOV. Coverage is collected daily for the stocks discussed on Reddit.
Rating and target changes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Aug 6, 2026 | UBS | Raised target | Neutral | $4.75 → $5.00 |
| Jul 21, 2026 | Canaccord Genuity | Raised target | Buy | $4.20 → $5.50 |
| Jun 11, 2026 | UBS | Raised target | Neutral | $2.75 → $4.75 |
| Jun 4, 2026 | Canaccord Genuity | Raised target | Buy | $3.20 → $4.20 |
| Mar 20, 2026 | Canaccord Genuity | Lowered target | Buy | $3.70 → $3.20 |
| Mar 5, 2026 | Leerink Partners | Lowered target | Market Perform | $3.00 → $2.50 |
| Jan 20, 2026 | Canaccord Genuity | Reiterated | Buy | $3.70 |
| Nov 6, 2025 | Canaccord Genuity | Lowered target | Buy | $4.10 → $3.70 |
Source: Yahoo Finance analyst data, collected daily.